GlobeNewsWire
30 Jul 2026, 02:26 UTC · 14w ago
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
Impact · against what's priced in
The announcement of shareholder litigation investigations into Arcus Biosciences, CG Oncology, and Exelixis introduces fresh governance and legal risks. These probes into fiduciary breaches and self-dealing create uncertainty and potential liability that likely outweigh the immediate impact of the announcements.
- CGON−0.30
No priced-in read yet





